about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

Eli Lil­ly re-ups di­ver­si­ty pledge, pitch­ing in $30M to ven­ture fund for mi­nor­i­ty-owned health­care firms

5 years ago
Financing
Pharma

Am­gen tops cost watch­dog's price gougers list based on 'un­sup­port­ed' in­creas­es for En­brel with­out mean­ing­ful da­ta

5 years ago
Pharma

Mark Cuban jumps out of the Shark Tank and in­to gener­ic phar­ma with a plan to of­fer dirt-cheap drugs

5 years ago
People

#JPM21: Al­bert Bourla pre­pares Pfiz­er to set­tle in to next phase post-Up­john, but that does­n't mean he's rul­ing out ...

5 years ago
People
Pharma

Am­gen ponies up $240M for Michi­gan dis­cov­ery out­fit's den­drit­ic cell tar­get­ing mol­e­cules for au­toim­mune dis­or­ders

5 years ago
Deals

With KRAS break­through on the hori­zon, Am­gen's David Reese re­flects on so­tora­si­b's loom­ing re­view date and murky ...

5 years ago
People
R&D

Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

5 years ago
Pharma

No­var­tis brings BeiGene's promis­ing check­point in­hibitor in­to the fold, but what about high­ly tout­ed spar­tal­izum­ab?

5 years ago
Deals

With mR­NA proof of con­cept on dis­play in Covid-19, Mod­er­na plots HIV vac­cine moon­shot as part of pipeline ex­pan­sion

5 years ago
R&D

Covid-19 roundup: Pfiz­er, BioN­Tech set new pro­duc­tion quo­ta for vac­cine at 2B dos­es in 2021; New da­ta show IL-6 ...

5 years ago
Coronavirus

EQRx scores $500M to dri­ve its dis­rup­tive drug pric­ing mod­el and late-stage on­col­o­gy hope­fuls to mar­ket

5 years ago
Deals

News brief­ing: Sanofi ponies up more mon­ey to ex­pand pro­tein degra­da­tion col­lab with Nurix; Bio­gen fires shot at ...

5 years ago
News Briefing

FDA side­swipes Ne­oleukin with clin­i­cal hold on lead im­munother­a­py can­di­date, sends shares plum­met­ing

5 years ago
R&D
FDA+

Chimerix places its bets on On­co­ceu­tic­s' dopamine an­tag­o­nist for rare brain can­cer in quest to sal­vage its im­age

5 years ago
Deals

News brief­ing: Pfiz­er kick­starts PhI­II tri­al for DMD gene ther­a­py, out­rac­ing Sarep­ta; Teva's re­for­mu­lat­ed ...

5 years ago
News Briefing

Al­ny­lam nears FDA fil­ing for 4th RNAi ther­a­py vutrisir­an af­ter late-stage da­ta back use in pro­tein mis­fold­ing ...

5 years ago
R&D

Bris­tol My­ers Squibb ices li­cens­ing pact with Ar­se­nal­Bio to draft its de­sign­er T cells in­to the sol­id tu­mor fight

5 years ago
Deals
R&D

As­traZeneca's Farx­i­ga gets rough FDA re­view date for ground­break­ing move in­to chron­ic kid­ney dis­ease

5 years ago
FDA+

New year, new me: Pfiz­er aban­dons icon­ic 'blue pil­l' lo­go in fa­vor of sleek­er — if more am­bigu­ous — new de­sign

5 years ago
Pharma

Ab­b­Vie eyes Hu­mi­ra match­ing move in­to pso­ri­at­ic arthri­tis for im­munol­o­gy fol­low-up Skyrizi

5 years ago
R&D

Re­gen­eron's Schleifer, Yan­copou­los set their com­pa­ny's am­bi­tions sky high with $1.4B on the ta­ble in per­for­mance ...

5 years ago
People

Ab­b­Vie bails on So­sei Hep­tares pact for nov­el neu­rol­o­gy can­di­dates in blow to dis­cov­ery out­fit's A-list Rolodex

5 years ago
Deals

In quick start to new year's M&A, Arvelle Ther­a­peu­tics hands reins to An­geli­ni as it nears EU ap­proval for cenoba­mate

5 years ago
Deals
R&D

Bris­tol My­ers Squibb walks on Op­di­vo's FDA nod for small-cell lung can­cer af­ter mid­dling OS da­ta could­n't back ...

5 years ago
Pharma
FDA+
First page Previous page 171819202122 Next page Last page
A service from the Financial Times